224
· DOS Abstracts
Differences in MACI® Patient Characteristics in
European Countries
Casper Bindzus Foldager, Martin Lind
Orthopaedic Research Lab, Aarhus University Hospital; Sports Trauma Clinic,
Aarhus University Hospital
Background:
Matrix-Assisted Chondrocyte Implantation (MACI®) is a com-
mercially available cell- based technique for treatment of articular cartilage de-
fects. Randomized controlled trials has suggests the use of this treatment for
younger patients with focal cartilage lesions in the knee larger than 3cm2.
Purpose / Aim of Study:
To investigate demographics and cartilage defect
sizes of patients receiving MACI® treatment in the knee in European countries.
Materials and Methods:
Data was obtained from the Sanofi™ database on
patients receiving autologous chondrocyte cultured in the European Sanofi™
facility in Copenhagen, Denmark. Countries with more than ten patients treat-
ed from 2008-2013 were included. Patient demographics (age, gender) and
cartilage defect characteristics (size, number of defects) were evaluated. Data
was analyzed using one-way ANOVA analyses. P-values < 0.05 were considered
significant.
Findings / Results:
A total of 1909 patients from 9 European countries, in-
cluding Denmark, were eligible for evaluation. The average age was 35.5 years
(range 11-65) and male:female ratio of 67:33. Mean defect size was 5.70 cm2
(range 0.16-47cm2). Single defects accounted for 78% while 22% were mul-
tifocal. There were significant differences in mean cartilage defect size between
the countries (p<0.0001),. On average 18.9% were small cartilage defects
(<3cm2) of which 63.1% were <2cm2. Eleven percent of the cartilage defects
were large (>10cm2), and thus the majority of the defects were 3-10cm2
(70%).
Conclusions:
This study show differences in sizes of the cartilage defects in
patients receiving MACI® treatment in 9 European countries. In general the
treatments are being assigned to patients matching criteria in age and defect
size for which evidence have suggested benefit of chondrocyte transplantation
compared with alternative treatments.
171.
